BioLineRx Announces U.S. FDA Acceptance of New Drug Application for Aphexda (motixafortide) in Stem Cell Mobilization
PDUFA target action date set for September 9, 2023
NDA submission based on GENESIS Phase 3 trial data that met all primary and secondary endpoints with a high level of statistical significance
Company advancing preparations for robust commercial...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | New Drug Applications | Statistics | Stem Cell Therapy | Stem Cells